Cargando…

Allergists and COVID-vaccine: which is the actual risk of reactions in allergic patients?

Detalles Bibliográficos
Autores principales:	Pucciarini, Francesco, Barone, Alessandro, Incorvaia, Cristoforo, Erminia, Ridolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mattioli 1885 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9686174/ https://www.ncbi.nlm.nih.gov/pubmed/36300230 http://dx.doi.org/10.23750/abm.v93i5.13006

Ejemplares similares

The quest for improving general and in hospital health care during COVID-19 pandemic
por: Ridolo, Erminia, et al.
Publicado: (2021)

Current treatment strategies for seasonal allergic rhinitis: where are we heading?
por: Ridolo, Erminia, et al.
Publicado: (2022)

Dermatological manifestations during COVID-19 infection: a case series and discussion on the problem of differential diagnosis
por: Ridolo, Erminia, et al.
Publicado: (2021)

Lipid transfer protein syndrome: How to save a life through careful education
por: Ridolo, Erminia, et al.
Publicado: (2022)

Climate Change, Migration, and Allergic Respiratory Diseases: An Update for the Allergist
por: D'Amato, Gennaro, et al.
Publicado: (2011)

Venom Immunotherapy and Aeroallergen Immunotherapy: How Do Their Outcomes Differ?
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Patient's Adherence and Compliance and Quality of Life During/After VIT
por: Incorvaia, Cristoforo, et al.
Publicado: (2022)

Pharmacoeconomics of sublingual immunotherapy with the 5-grass pollen tablets for seasonal allergic rhinitis
por: Lombardi, Carlo, et al.
Publicado: (2017)

Parietaria Allergy: An Intriguing Challenge for the Allergist
por: Ciprandi, Giorgio, et al.
Publicado: (2018)

Local allergic rhinitis: evolution of concepts
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
por: Incorvaia, Cristoforo, et al.
Publicado: (2023)

Which immunotherapy product is better for patients allergic to Polistes venom? A laboratory and clinical study
por: Savi, Eleonora, et al.
Publicado: (2017)

Skin reaction to COVID-19 vaccine: A report of 4 cases
por: Bertolani, Mariabeatrice, et al.
Publicado: (2022)

Will Research on COVID-19 Stimulate the Identification of Immunological Mechanisms Underlying Some Protective Effects?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Adherence issues related to sublingual immunotherapy as perceived by allergists
por: Scurati, Silvia, et al.
Publicado: (2010)

Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults
por: Ridolo, Erminia, et al.
Publicado: (2019)

Can the Pattern of Early Sensitization to Allergen Molecules Drive a New Approach for Prevention of Allergy?
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

Preventive actions of allergen immunotherapy: the facts and the effects in search of evidence
por: Martignago, Irene, et al.
Publicado: (2017)

Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

To prevent the allergic disease: the dream of the allergist
por: Ciprandi, Giorgio, et al.
Publicado: (2020)

New combinations in the treatment of COPD: rationale for aclidinium–formoterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

About the effect of pulmonary rehabilitation on lung function in patients with chronic obstructive pulmonary disease
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

IgE Depletion in Severe Asthma: What We Have and What Could Be Added in the Near Future
por: Incorvaia, Cristoforo, et al.
Publicado: (2017)

New product development with the innovative biomolecular sublingual immunotherapy formulations for the management of allergic rhinitis
por: Frati, Franco, et al.
Publicado: (2014)

Elicitors of severe allergic reactions – reports from allergists and emergency doctors
por: Hohenadel, M., et al.
Publicado: (2017)

Allergists Can Safely Evaluate and Revaccinate Individuals With Immediate Allergic Reactions to mRNA COVID-19 Vaccines
por: Greenhawt, Matthew, et al.
Publicado: (2021)

Two decades with omalizumab: what we still have to learn
por: Incorvaia, Cristoforo, et al.
Publicado: (2018)

What still prevents to acknowledge a major role for pulmonary rehabilitation in COPD treatment?
por: Incorvaia, Cristoforo, et al.
Publicado: (2019)

Importance of hypersensitivity in adverse reactions to drugs in the elderly
por: Ventura, Maria Teresa, et al.
Publicado: (2018)

Is allergic sensitization relevant in severe asthma? Which allergens may be culprit?
por: Lombardi, Carlo, et al.
Publicado: (2017)

Bilastine: new insight into antihistamine treatment
por: Ridolo, Erminia, et al.
Publicado: (2015)

Personalized medicine and allergen immunotherapy: the beginning of a new era?
por: Incorvaia, Cristoforo, et al.
Publicado: (2021)

Striving for optimal bronchodilation: focus on olodaterol
por: Incorvaia, Cristoforo, et al.
Publicado: (2016)

Role of indacaterol and the newer very long-acting β2-agonists in patients with stable COPD: a review
por: Ridolo, Erminia, et al.
Publicado: (2013)

207 Approach of Paediatric Allergists to Allergen Immunotherapy in Severe Persistent Allergic Rhinitis
por: Fiocchi, Alessandro, et al.
Publicado: (2012)

The Present and Future of Allergen Immunotherapy in Personalized Medicine
por: Ridolo, Erminia, et al.
Publicado: (2022)

Dermatology for the Allergist
por: Kim, Dennis, et al.
Publicado: (2010)

Patient’s compliance with allergen immunotherapy
por: Incorvaia, Cristoforo, et al.
Publicado: (2008)

Omalizumab, an anti-immunoglobulin E antibody: state of the art
por: Incorvaia, Cristoforo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jukiav0jfncg9achd10q5v72ro